@article{MTMT:34684406,
	title = {Individual benefit in heart sparing during DIBH-supported left breast radiotherapy},
	url = {https://m2.mtmt.hu/api/publication/34684406},
	author = {Gaál, Szilvia and Kahán, Zsuzsanna and Rárosi, Ferenc and Fodor, Gergely and Tolnai, József and Deák , Bence and Hideghéty, Katalin and Varga, Zoltán},
	doi = {10.1016/j.ctro.2024.100746},
	journal-iso = {CLIN TRANSL RADIAT ONCOL (CTRO)},
	journal = {CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY},
	volume = {46},
	unique-id = {34684406},
	year = {2024},
	eissn = {2405-6308},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775; Rárosi, Ferenc/0000-0002-1014-9242; Fodor, Gergely/0000-0002-4736-4966; Tolnai, József/0000-0002-7648-764X; Hideghéty, Katalin/0000-0001-7080-2365; Varga, Zoltán/0000-0001-8537-6282}
}

@article{MTMT:34513250,
	title = {Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients},
	url = {https://m2.mtmt.hu/api/publication/34513250},
	author = {Pascual, Javier and Gil-Gil, Miguel and Proszek, Paula and Zielinski, Christoph and Reay, Alistair and Ruiz-Borrego, Manuel and Cutts, Rosalind and Ciruelos Gil, Eva M and Feber, Andrew and Muñoz-Mateu, Montserrat and Swift, Claire and Bermejo, Begoña and Herranz, Jesus and Margeli Vila, Mireia and Antón, Antonio and Kahán, Zsuzsanna and Csöszi, Tibor and Liu, Yuan and Fernandez-Garcia, Daniel and Garcia-Murillas, Isaac and Hubank, Michael and Turner, Nicholas C and Martín, Miguel},
	doi = {10.1158/1078-0432.CCR-23-0956},
	journal-iso = {CLIN CANCER RES},
	journal = {CLINICAL CANCER RESEARCH},
	volume = {29},
	unique-id = {34513250},
	issn = {1078-0432},
	abstract = {Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations between baseline genomic landscape and on-treatment ctDNA dynamics with treatment efficacy.Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model.201 patients were profiled at baseline, with ctDNA detection associated with worse progression-free survival (PFS)/overall survival (OS). Detectable TP53 mutation showed worse PFS and OS in both treatment arms, even after restricting population to baseline ctDNA detection. ESR1 mutations were associated with worse OS overall, which was lost when restricting population to baseline ctDNA detection. PIK3CA mutations confer worse OS only to patients on the palbociclib+fulvestrant treatment arm. ctDNA dynamics analysis (n = 120) showed higher ctDNA suppression in the capecitabine arm. Patients without ctDNA suppression showed worse PFS in both treatment arms.We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with hormone receptor-positive/HER2-negative metastatic breast cancer harboring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted.},
	year = {2023},
	eissn = {1557-3265},
	pages = {4166-4177},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775}
}

@article{MTMT:33814839,
	title = {Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort},
	url = {https://m2.mtmt.hu/api/publication/33814839},
	author = {Pipek, Orsolya Anna and Alpár, Donát and Rusz, Orsolya and Bödör, Csaba and Udvarnoki, Zoltán András and Medgyes-Horváth, Anna and Csabai, István and Szállási, Zoltán and Madaras, Lilla and Kahán, Zsuzsanna and Cserni, Gábor and Kővári, Bence and Kulka, Janina and Tőkés, Anna-Mária},
	doi = {10.3390/ijms24108553},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {33814839},
	issn = {1661-6596},
	abstract = {A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Pipek, Orsolya Anna/0000-0001-8109-0340; Rusz, Orsolya/0000-0001-5726-4072; Bödör, Csaba/0000-0002-0729-692X; Udvarnoki, Zoltán András/0000-0001-7086-235X; Medgyes-Horváth, Anna/0000-0003-4435-5797; Csabai, István/0000-0001-9232-9898; Szállási, Zoltán/0000-0001-5395-7509; Madaras, Lilla/0000-0002-4137-4696; Kahán, Zsuzsanna/0000-0002-5021-8775; Cserni, Gábor/0000-0003-1344-7744; Kővári, Bence/0000-0002-4498-8781; Kulka, Janina/0000-0001-6498-5943; Tőkés, Anna-Mária/0000-0002-9581-7536}
}

@article{MTMT:33647465,
	title = {Corrigendum : Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer},
	url = {https://m2.mtmt.hu/api/publication/33647465},
	author = {Rubovszky, Gábor and Kocsis, Judit and Boér, Katalin and Chilingirova, Nataliya and Dank, Magdolna and Kahán, Zsuzsanna and Kaidarova, Dilyara and Kövér, Erika and Krakovská, Bibiana Vertáková and Máhr, Károly and Mriňáková, Bela and Pikó, Béla and Božović-Spasojević, Ivana and Horváth, Zsolt},
	doi = {10.3389/pore.2023.1610954},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {29},
	unique-id = {33647465},
	issn = {1219-4956},
	keywords = {guideline; Early breast cancer; Metastatic breast cancer; adjuvant treatment; inflammatory breast cancer; locally advanced breast cancer; Neoadjuvant treatment},
	year = {2023},
	eissn = {1532-2807},
	orcid-numbers = {Rubovszky, Gábor/0000-0003-1723-5589; Boér, Katalin/0000-0002-5101-7289; Dank, Magdolna/0000-0002-4442-8733; Kahán, Zsuzsanna/0000-0002-5021-8775; Horváth, Zsolt/0000-0002-5376-7737}
}

@article{MTMT:32961748,
	title = {Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer},
	url = {https://m2.mtmt.hu/api/publication/32961748},
	author = {Kahán, Zsuzsanna and Szanto, Istvan and Dudas, Rita and Kapitány, Zsuzsanna and Molnar, Maria and Koncz, Zsuzsa and Mailáth, Mónika},
	doi = {10.3389/pore.2022.1610391},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {28},
	unique-id = {32961748},
	issn = {1219-4956},
	abstract = {Follow-up includes ongoing contact with and health education of the patient, surveillance and control of the adverse effects of surgery, oncological therapies or radiotherapy, screening of metachronous cancers, and comprehensive (physical, psychological and social) patient rehabilitation, which may be enhanced by a healthy lifestyle. Primary attention should be paid to early detection and, when needed, curative treatment of local/regional tumour recurrences. Similarly, with the hope of curative solution, it is important to recognize the entity of a low-mass and relatively indolent recurrence or metastasis (oligometastasis); however, there is still no need to investigate distant metastases by routine diagnostic imaging or assess tumour markers. Below there is a list of possible sources of support, with respect to adjuvant hormone therapy continued during long-term care, social support resources, pivotal points and professional opportunities for physical and mental rehabilitation. Individual solutions for specific issues (breast cancer risk/genetic mutation, pregnancy) are provided by constantly widening options. Ideally, a complex breast cancer survivorship programme is practised by a specially trained expert supported by a cooperative team of oncologists, surgeons, breast radiologists, social workers, physiotherapists, psycho-oncologists and psychiatrists. The approach of follow-up should be comprehensive and holistic.},
	keywords = {FOLLOW-UP; Healthy lifestyle; physical rehabilitation; Social rehabilitation; psychosocial oncology care; side-effect management},
	year = {2022},
	eissn = {1532-2807},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775; Koncz, Zsuzsa/0000-0003-1518-7253; Koncz, Zsuzsa/0000-0003-1518-7253}
}

@article{MTMT:32952088,
	title = {Diversity of breast cancers begins at imaging...},
	url = {https://m2.mtmt.hu/api/publication/32952088},
	author = {Kahán, Zsuzsanna},
	doi = {10.1016/j.ejrad.2022.110362},
	journal-iso = {EUR J RADIOL},
	journal = {EUROPEAN JOURNAL OF RADIOLOGY},
	volume = {154},
	unique-id = {32952088},
	issn = {0720-048X},
	year = {2022},
	eissn = {1872-7727},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775}
}

@article{MTMT:32946435,
	title = {Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer},
	url = {https://m2.mtmt.hu/api/publication/32946435},
	author = {Rubovszky, Gábor and Kocsis, Judit and Boér, Katalin and Chilingirova, Nataliya and Dank, Magdolna and Kahán, Zsuzsanna and Kaidarova, Dilyara and Kövér, Erika and Krakovská, Bibiana Vertáková and Máhr, Károly and Mriňáková, Bela and Pikó, Béla and Božović-Spasojević, Ivana and Horváth, Zsolt},
	doi = {10.3389/pore.2022.1610383},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {28},
	unique-id = {32946435},
	issn = {1219-4956},
	year = {2022},
	eissn = {1532-2807},
	orcid-numbers = {Rubovszky, Gábor/0000-0003-1723-5589; Boér, Katalin/0000-0002-5101-7289; Dank, Magdolna/0000-0002-4442-8733; Kahán, Zsuzsanna/0000-0002-5021-8775; Horváth, Zsolt/0000-0002-5376-7737; Krenács, Tibor/0000-0001-9164-065X; Kulka, Janina/0000-0001-6498-5943; Polgár, Csaba/0000-0001-7245-0762; Koncz, Zsuzsa/0000-0003-1518-7253}
}

@article{MTMT:32913015,
	title = {Radiotherapy of Breast Cancer—Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer},
	url = {https://m2.mtmt.hu/api/publication/32913015},
	author = {Polgár, Csaba and Kahán, Zsuzsanna and Ivanov, Olivera and Chorváth, Martin and Ligačová, Andrea and Csejtei, András and Gábor, Gabriella and Landherr, László and Mangel, László Csaba and Mayer, Árpád and Fodor, János},
	doi = {10.3389/pore.2022.1610378},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {28},
	unique-id = {32913015},
	issn = {1219-4956},
	abstract = {The international radiotherapy (RT) expert panel has revised and updated the RT guidelines that were accepted in 2020 at the 4th Hungarian Breast Cancer Consensus Conference, based on new scientific evidence. Radiotherapy after breast-conserving surgery (BCS) is indicated in ductal carcinoma in situ (stage 0), as RT decreases the risk of local recurrence (LR) by 50-60%. In early stage (stage I-II) invasive breast cancer RT remains a standard treatment following BCS. However, in elderly (≥70 years) patients with stage I, hormone receptor-positive tumour, hormonal therapy without RT can be considered. Hypofractionated whole breast irradiation (WBI) and for selected cases accelerated partial breast irradiation are validated treatment alternatives to conventional WBI administered for 5 weeks. Following mastectomy, RT significantly decreases the risk of LR and improves overall survival of patients who have 1 to 3 or ≥4 positive axillary lymph nodes. In selected cases of patients with 1 to 2 positive sentinel lymph nodes axillary dissection can be substituted with axillary RT. After neoadjuvant systemic treatment (NST) followed by BCS, WBI is mandatory, while after NST followed by mastectomy, locoregional RT should be given in cases of initial stage III-IV and ypN1 axillary status.},
	year = {2022},
	eissn = {1532-2807},
	orcid-numbers = {Polgár, Csaba/0000-0001-7245-0762; Kahán, Zsuzsanna/0000-0002-5021-8775}
}

@article{MTMT:32838847,
	title = {Brachyterápiás Acuros BV és TG-43 formalizmus összehasonlítása HDR cervixkezeléseknél},
	url = {https://m2.mtmt.hu/api/publication/32838847},
	author = {Nagy, Zoltán and Laboda, Brigitta and Antal, Gergely and Toller, Gábor and Kahán, Zsuzsanna and Cselik, Zsolt},
	journal-iso = {MAGYAR ONKOLÓGIA},
	journal = {MAGYAR ONKOLÓGIA},
	volume = {66},
	unique-id = {32838847},
	issn = {0025-0244},
	year = {2022},
	eissn = {2060-0399},
	pages = {74-74},
	orcid-numbers = {Antal, Gergely/0000-0002-9259-6643; Kahán, Zsuzsanna/0000-0002-5021-8775}
}

@article{MTMT:32546756,
	title = {Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL},
	url = {https://m2.mtmt.hu/api/publication/32546756},
	author = {Martin, M. and Zielinski, C. and Ruiz-Borrego, M. and Carrasco, E. and Turner, N. and Ciruelos, E.M. and Muñoz, M. and Bermejo, B. and Margeli, M. and Anton, A. and Kahán, Zsuzsanna and Csöszi, T. and Casas, M.I. and Murillo, L. and Morales, S. and Alba, E. and Gal-Yam, E. and Guerrero-Zotano, A. and Calvo, L. and de la Haba-Rodriguez, J. and Ramos, M. and Alvarez, I. and Garcia-Palomo, A. and Huang Bartlett, C. and Koehler, M. and Caballero, R. and Corsaro, M. and Huang, X. and Garcia-Sáenz, J.A. and Chacón, J.I. and Swift, C. and Thallinger, C. and Gil-Gil, M.},
	doi = {10.1016/j.annonc.2020.12.013},
	journal-iso = {ANN ONCOL},
	journal = {ANNALS OF ONCOLOGY},
	volume = {32},
	unique-id = {32546756},
	issn = {0923-7534},
	year = {2021},
	eissn = {1569-8041},
	pages = {488-499},
	orcid-numbers = {Kahán, Zsuzsanna/0000-0002-5021-8775}
}